Clinical Trials - March 23, 2016
AZ reports results from the Brilinta SOCRATES trial
AstraZeneca announces results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique(ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA). The primary efficacy endpoint of time to first occurrence of any event from the composite of stroke (ischaemic or haemorrhagic), myocardial […]
Clinical Trials - January 22, 2015
Astra’s Brilinta Gets a Boost
On the heels of positive outcomes from a second study of the blood thinner Brilinta, AstraZeneca plans to use the results to bolster an application to the U.S. Food and Drug Administration (FDA) to expand and extend the use of the anti-platelet drug. Called the Pegasus study, it followed 21,000 patients who’d had heart attacks and found that long-term use of Brilinta in […]
Drug Development Pharma - August 19, 2014
No investigation of Brilinta
The United States Department of Justice has announced that it closes its investigation into PLATO clinical trial for AstraZeneca’s Brilinta. In the PLATO study, Brilinta (ticagrelor) was compared to clopidrogel combined with acetylsalicylic acid. The studied showed that ticagrelor reduced cardiovascular events better than the rival. The Department of Justice started an investigation in October 2013 […]
Drug Development Pharma - November 8, 2013
EMA seeks information on AstraZeneca’s Brilinta
The European Medicines Agency has contacted AstraZeneca asking the company to provide more information about a U.S. probe into a clinical trial of the company’s new blood thinner Brilinta (ticagrelor), reports Reuters. On November 7 EMA said that it contacted AstraZeneca earlier after the U.S. Department of Justice probe was disclosed by the company on October […]
